SCHEMBL10078098

SCHEMBL10078098

CCCCc1c(N2CCNCC2)c(=O)c1=O

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
CETP P11597 1/20 0.37
GNAI3 P08754 2/20 0.36
GNAO1 P09471 2/20 0.36
GNAI1 P63096 2/20 0.36
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
LMNA P02545 1/20 0.35
HTR2C P28335 2/20 0.35
HTR2B P41595 2/20 0.35
ABCB1 P08183 1/20 0.34
CCR4 P51679 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
ADRB1 P08588 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4713410 0.73 HRH2 (0.39) GNAI3GNAO1GNAI1ALDH1A1MAPT
SCHEMBL21231245 0.73 ALDH1A1 (0.60) KDM4EGNAI3GNAO1GNAI1ALDH1A1
SCHEMBL8240682 0.72 ALDH1A1 (0.55) GNAI3GNAO1GNAI1ALDH1A1MAPT
SCHEMBL3411557 0.69 TYMP (0.45) KDM4EALDH1A1MAPTLMNA
SCHEMBL8243898 0.68 ALDH1A1 (0.38) KDM4EALDH1A1LMNAHTR2CHTR2B
SCHEMBL10078401 0.68 TAAR1 (0.50) CETPHTR2CHTR2BADRB1
Hydrochloric Acid SCHEMBL22320273 0.67 ALDH1A1 (0.39) KDM4EALDH1A1MAPTLMNAHTR2C
SCHEMBL13467421 0.65 ALDH1A1 (0.42) KDM4EALDH1A1LMNA
SCHEMBL3942886 0.65 ALDH1A1 (0.43) KDM4EALDH1A1MAPTLMNAHTR2C
SCHEMBL10078402 0.65 ALDH1A1 (0.39) ALDH1A1LMNACCR4ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013170-B1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2012-06-27 EP disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
WO-2007127731-A1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-08 WO disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents MAVS, MTAP, SAMHD1 KDM4E 1248/4885CETP 1450/4885GNAI3 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.